Initial Treatment Sample Clauses

Initial Treatment. The initial treatment and care of athletic injuries that occur during Apex AP’s coverage of events will be provided by Apex AP’s Athletic Trainer. Apex AP agrees that injuries, which warrant physical evaluations, will be seen by a physician to provide medical diagnosis and treatment. CCHS and Apex AP also agree that injuries that warrant emergency transport by city or state emergency professionals will be at the discretion of Apex AP. Apex AP agrees to give notice to students-athletes, parents, and guardians that visits to a physician’s office may be medically necessary; the policies of each physician’s office will determine the cost of the visit. Apex AP and shall not be liable or responsible for any medical costs connected with any student-athlete, including any potential emergency transport by city or state emergency health professionals.
Sample 1
AutoNDA by SimpleDocs
Initial Treatment. (Cycles 1–6) Study Cycles 1–6, Day 1 (CX.D1) (±2 days) • Within 72 hours prior to treatment, collect blood samples for the following analyses: — CBC — Serum chemistry • Problem-oriented PE, including xxxxx xxxxx (T, BP, RR, HR), ECOG performance status assessment and weight • Administer the following study medications according to the procedures in §7.3 — Cetuximab — Cisplatin or carboplatin — 5-FU • Assess adverse events1 and update concomitant medications • Continue 5-FU infusion according to the procedures in §7.3 • Administer the following study medications according to the procedures in §7.3 — IP — Cetuximab • Assess adverse events and update concomitant medications 1 DLTs will be assessed for all subjects, until at least six subjects randomized to receive VTX-2337 have received one cycle of treatment and the DSMB has completed the assessment of the starting dose. (§9.2.2) • Pre-dose — Collect blood sample for PK assessment (C1D8 only) — Collect blood sample for immune biomarker assessment • 45 minutes post IP dose (±15 min) — Collect blood samples for PK assessment (C1D8 only) • 1 hour post IP dose (±15 min) — Obtain 12-lead ECG • 8 hours post IP dose (±15 min) — Collect blood sample for PK assessment (C1D8 only) — Collect blood sample for immune biomarker assessment Study Cycles 1–6, Week 12 (± 3 days) and Week 18 (± 3 days) • Perform CT / MRI of neck, chest, upper abdomen, and other anatomical region(s) of disease using the same technique as baseline and in accordance with the Imaging Manual Imaging should not be delayed in case of missed doses or dose delays.
Sample 1

Related to Initial Treatment

  • Equal Treatment No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered and paid to all the Subscribers and their permitted successors and assigns.

  • National Treatment In the sectors inscribed in its Schedule, and subject to any conditions and qualifications set out therein, each Party shall accord to services and service suppliers of the other Party treatment no less favourable than that it accords, in like circumstances, to its own services and service suppliers.

  • Confidential Treatment The parties hereto understand that any information or recommendation supplied by the Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Investment Manager, the Company or such persons the Investment Manager may designate in connection with the Fund. The parties also understand that any information supplied to the Sub-Adviser in connection with the performance of its obligations hereunder, particularly, but not limited to, any list of securities which may not be bought or sold for the Fund, is to be regarded as confidential and for use only by the Sub-Adviser in connection with its obligation to provide investment advice and other services to the Fund.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • Equal Treatment of Purchasers No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

  • Equal Treatment of Investors No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Investor by the Company and negotiated separately by each Investor, and is intended for the Company to treat the Investors as a class and shall not in any way be construed as the Investors acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State. (2) In addition, each Contracting Party shall accord to investors of the other Contracting Party, including in respect of returns on their investments, treatment which shall not be less favourable than that accorded to investors of any third State. (3) The provisions of paragraphs (1) and (2) above shall not be construed so as to oblige one Contracting Party to extend to the investors of the other the benefit of any treatment, preference or privilege resulting from: (a) Any existing or future free trade area, customs unions, monetary union or similar international agreement or other forms of regional cooperation to which one of the Contracting Parties is or may become a party, or (b) Any matter pertaining wholly or mainly to taxation.

  • CONFIDENTIAL TREATMENT REQUESTED Confidential portions of this document have been redacted and have been separately filed with the Commission.

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!